UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Journal of clinical oncology, 2000-01, Vol.18 (1), p.158-166

2000

Volltextzugriff (PDF)

Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

Journal of clinical oncology, 2004-01, Vol.22 (1), p.53-61

2004

Volltextzugriff (PDF)

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

European journal of cancer (1990), 2017-02, Vol.72, p.S128-S129

2017

Volltextzugriff (PDF)

Sentinel node status predicts survival in thick melanomas: The Oxford perspective

European journal of surgical oncology, 2012-10, Vol.38 (10), p.936-942

2012

Volltextzugriff (PDF)

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2551-2557

2003

Volltextzugriff (PDF)

300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S53-S54

2015

Volltextzugriff (PDF)

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

Annals of oncology, 2018-02, Vol.29 (2), p.490-496

2018

Volltextzugriff (PDF)

1125P Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy

Annals of oncology, 2023-10, Vol.34, p.S676-S676

2023

Volltextzugriff (PDF)

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

Annals of oncology, 2015-04, Vol.26 (4), p.624-644

2015

Volltextzugriff (PDF)

17P Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade

Annals of oncology, 2023-10, Vol.34, p.S192-S192

2023

Volltextzugriff (PDF)

135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)

Annals of oncology, 2023-10, Vol.34, p.S235-S235

2023

Volltextzugriff (PDF)

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Annals of oncology, 2015-04, Vol.26 (4), p.804-811

2015

Volltextzugriff (PDF)

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

Annals of oncology, 2015-10, Vol.26 (10), p.2173-2179

2015

Volltextzugriff (PDF)

155P The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)

Annals of oncology, 2024-09, Vol.35, p.S277-S277

2024

Volltextzugriff (PDF)

734MO Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy

Annals of oncology, 2022-09, Vol.33, p.S878-S879

2022

Volltextzugriff (PDF)

827P An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results

Annals of oncology, 2022-09, Vol.33, p.S926-S927

2022

Volltextzugriff (PDF)

Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study

Annals of oncology, 2019-10, Vol.30, p.v547-v548

2019

Volltextzugriff (PDF)

1342P - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study

Annals of oncology, 2019-10, Vol.30, p.v547-v548

2019

Volltextzugriff (PDF)

Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial

International journal of radiation oncology, biology, physics, 2022-04, Vol.112 (5), p.e8-e9

2022

Volltextzugriff (PDF)

1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Annals of oncology, 2023-10, Vol.34, p.S669-S670

2023

Volltextzugriff (PDF)

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

Annals of oncology, 2023-10, Vol.34, p.S667-S668

2023

Volltextzugriff (PDF)

IGNYTE: A Phase 1/2 Multi-Cohort Clinical Trial of RP1 ± Nivolumab in Patients with Non-Small Cell Lung Cancer and Other Solid Tumors

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.e12-e13

2022

Volltextzugriff (PDF)

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

Annals of oncology, 2021-09, Vol.32, p.S865-S866

2021

Volltextzugriff (PDF)

527P Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)

Annals of oncology, 2021-09, Vol.32, p.S594-S594

2021

Volltextzugriff (PDF)

66O Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers

Annals of oncology, 2024-09, Vol.35, p.S239-S240

2024

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(92)
Tagungsberichte
(1)

Sprache

Englisch
(91)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(31)
Humans
(25)
Male
(21)
Female
(19)
Oncology
(18)
Aged
(16)
Adult
(13)
Middle Aged
(12)
Aged, 80 And Over
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Melanoma - Drug Therapy
(10)
Treatment Outcome
(9)
Melanoma - Pathology
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Melanoma - Mortality
(7)
Skin Neoplasms - Drug Therapy
(7)
Disease-Free Survival
(6)
Follow-Up Studies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Sentinel node status predicts survival in thick melanomas: The Oxford perspective

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma

300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

1125P Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

17P Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade

135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

155P The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)

734MO Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy

827P An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results

Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study

1342P - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study

Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial

1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

IGNYTE: A Phase 1/2 Multi-Cohort Clinical Trial of RP1 ± Nivolumab in Patients with Non-Small Cell Lung Cancer and Other Solid Tumors

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

527P Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)

66O Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers

Suchergebnisse filtern